ArticleNuclear medicine communications2026
The clinical value of interim PET/computed tomography scanning in patients with classical Hodgkin's lymphoma and its influence on prognosis in Duhok Province, Kurdistan Region - Northern Iraq.
Article in Nuclear medicine communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClassical Hodgkin's lymphoma (cHL) is a largely curable cancer, although a percentage of patients experience recurrence or treatment failure. Interim PET(iPET)/computed tomography (CT) scanning after 2-4 rounds of adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy has emerged as a useful predictor of treatment response and survival. The current study aimed to assess the prognostic significance of iPET/CT in patients with cHL treated at Azadi Hematology Oncology Center in Duhok Province, Kurdistan Region, and compare the results to worldwide data.
methodsThis retrospective analysis comprised 53 patients who had histologically proven cHL treatment between January 2020 and March 2024. PET/CT scans were performed on all patients at the intermediate and end of therapy stages. Deauville scoring was used to categorize the replies. Kaplan-Meier analysis was used to determine survival results.
resultsInterim complete metabolic response (iCR, Deauville 1-3) was observed in 83% of patients, with a corresponding end-of-treatment complete response rate of 93.2%. Patients with iCR had significantly improved overall survival (OS) and progression-free survival (PFS) compared to those with partial response or no response/progression (OS: P = 0.001; PFS: P < 0.001). The concordance rate between iPET/CT and final response was 90.6%.
conclusioniPET/CT is a reliable prognostic indicator in cHL and significantly correlates with OS and PFS. The findings support its use in response-adapted therapy in resource-limited settings like Duhok. These results align with international studies, reinforcing the utility of iPET/CT in guiding treatment modifications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.